Peng J, Xu H, Liu Q. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis. PLoS One 2024;19:e0312133.
PMID: 39423210